Education
About Us
Working with TipRanks
Follow Us
OptimizeRx Corporation (OPRX)
NASDAQ:OPRX
OPRX Stock Chart & Stats
$5.99
-$1.11(-19.07%)
At close: 4:00 PM EST
$5.99
-$1.11(-19.07%)
Day’s Range― - ―
52-Week Range$5.54 - $22.25
Previous CloseN/A
Volume200.46K
Average Volume (3M)498.06K
Market Cap
$112.39M
Enterprise Value$115.12M
Total Cash (Recent Filing)$23.36M
Total Debt (Recent Filing)$26.10M
Price to Earnings (P/E)44.3
Beta2.12
Next Earnings
Apr 30, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding18,762,203
10 Day Avg. Volume450,645
30 Day Avg. Volume498,064
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.77
Price to Sales (P/S)2.08
P/FCF Ratio12.19
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit1.66
Enterprise Value/Ebitda7.02
Forecast
1Y Price Target
$13.92Price Target Upside132.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.97
Revenue Forecast (FY)$121.63M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationOptimizeRx generated meaningful operating and free cash flow (~$18.7M in 2025), reversing prior volatility. Durable cash generation improves funding for debt reduction, execution of buybacks, and reinvestment in product/recurring offerings, increasing financial flexibility over the next 2–6 months.
Conservative Balance Sheet / Low LeverageVery low leverage (debt-to-equity ~0.04) and a sizable equity base give the company runway to absorb revenue variability without forcing near-term dilutive financing. This structural strength supports opportunistic buybacks and prioritizing strategic investments or further debt paydown.
High Customer Retention & ProductivityA 116% net revenue retention rate and rising revenue per employee signal strong client stickiness and operating leverage. These durable client relationships and productivity gains increase the likelihood of recurring revenue and steady margin expansion as subscription/enterprise deals scale.
Bears Say
Contracted Revenue Softness / Conservative GuidanceContracted revenue materially lags prior-year levels and management set flat-to-modest 2026 revenue guidance. Structurally weaker contracted bookings reduce visibility into topline growth and could constrain reinvestment or slow conversion to higher-recurring subscription revenue over the medium term.
Non-repeatable Managed Services RevenueA meaningful share of recent revenue was from managed-services projects (~$9M) that are not expected to recur. This structural mix shift removes a near-term revenue source and forces the company to replace one-off services with recurring offerings to sustain growth and margin consistency.
Shorter Contract Durations / Visibility RiskA shift to shorter-duration, pulse-style contracts lowers revenue visibility and increases churn and sales cadence. This structural client behavior can raise renewal and acquisition costs, making sustained margin and revenue growth harder without higher contract conversion to multi-period subscriptions.
OptimizeRx News
OPRX FAQ
What was OptimizeRx Corporation’s price range in the past 12 months?
OptimizeRx Corporation lowest stock price was $5.54 and its highest was $22.25 in the past 12 months.
What is OptimizeRx Corporation’s market cap?
OptimizeRx Corporation’s market cap is $112.39M.
When is OptimizeRx Corporation’s upcoming earnings report date?
OptimizeRx Corporation’s upcoming earnings report date is Apr 30, 2026 which is in 38 days.
How were OptimizeRx Corporation’s earnings last quarter?
OptimizeRx Corporation released its earnings results on Mar 05, 2026. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.224 by $0.286.
Is OptimizeRx Corporation overvalued?
According to Wall Street analysts OptimizeRx Corporation’s price is currently Undervalued.
Does OptimizeRx Corporation pay dividends?
OptimizeRx Corporation does not currently pay dividends.
What is OptimizeRx Corporation’s EPS estimate?
OptimizeRx Corporation’s EPS estimate is <0.01.
How many shares outstanding does OptimizeRx Corporation have?
OptimizeRx Corporation has 18,762,203 shares outstanding.
What happened to OptimizeRx Corporation’s price movement after its last earnings report?
OptimizeRx Corporation reported an EPS of $0.51 in its last earnings report, beating expectations of $0.224. Following the earnings report the stock price went down -10.491%.
Which hedge fund is a major shareholder of OptimizeRx Corporation?
Currently, no hedge funds are holding shares in OPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OptimizeRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.92 (132.39% Upside)
$13.92 (132.39% Upside)
Blogger Sentiment
Bullish
OPRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 9.5%
Last 30 Days ▼ 9.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.85%
12-Months-Change
Fundamentals
Return on Equity
4.22%
Trailing 12-Months
Asset Growth
3.36%
Trailing 12-Months
Company Description
OptimizeRx Corporation
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
OPRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial performance for 2025: strong cash generation, improved profitability, high net revenue retention (116%), productivity gains, meaningful DAAP momentum and a $10M share repurchase authorization. However, management flagged near-term top-line risks driven by a market shift away from managed services, conservative client behavior tied to MFN negotiations, shorter contract durations, and a Q4 gross margin mix that is unlikely to repeat. Guidance for 2026 is conservative on revenue (flat to modestly higher) while maintaining healthy adjusted EBITDA expectations, reflecting a focus on profitability and cash usage for debt reduction and opportunistic buybacks. Overall, the positives around profitability, cash flow, recurring-revenue progress and customer traction outweigh the near-term revenue headwinds.View all OPRX earnings summariesOPRX Stock 12 Month Forecast
Average Price Target
$13.92
▲(132.39% Upside)
Technical Analysis
Ownership Overview
6.46% Insiders
16.18% Mutual Funds
31.32% Other Institutional Investors
35.64% Public Companies and
Individual Investors